SYBX - Synlogic, Inc.
| Previous Close | 2.7400 |
| Open | 2.9500 |
| Bid | 0.0000 x 1000 |
| Ask | 0.0000 x 1200 |
| Day's Range | 2.6200 - 3.0000 |
| 52 Week Range | 1.9100 - 11.4270 |
| Volume | 863,940 |
| Avg. Volume | 254,987 |
| Market Cap | 91M |
| Beta (3Y Monthly) | 2.27 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.8010 |
| Earnings Date | Mar 10, 2020 - Mar 16, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8.81 |
- Business Wire
Synlogic Bridging Study Data with Solid Oral Formulation of SYNB1618, a Synthetic Biotic Approach to Treat Phenylketonuria, Demonstrate Improved Tolerability over Early Liquid Formulation and Guide to Next Stage of Clinical Development
Bridging Study Data from Synlogic's SYNB1618 PKU Candidate Demonstrate Improved Tolerability of New Solid Oral Formulation over Early Liquid
- American City Business Journals
Biotech accelerator teams with investment firm for $210M fund raise
A New York investment firm has raised $210 million for startups coming out of Boston-based biotech accelerator Xontogeny. It announced its first investment Tuesday: a $17 million early-stage funding of a local rare-disease startup.
- Thomson Reuters StreetEvents
Edited Transcript of SYBX earnings conference call or presentation 12-Nov-19 10:00pm GMT
Q3 2019 Synlogic Inc Earnings Call
- Business Wire
Synlogic to Webcast Presentation at the Piper Jaffray 31st Annual Healthcare Conference
Synlogic (SYBX) announced today that Aoife Brennan, M.B., B.Ch., Synlogic’s president and chief executive officer, will participate in a fireside chat at the Piper Jaffray 31st Annual Healthcare Conference at 11:30 am ET on Thursday, December 5, 2019, in New York City. A live webcast of the presentation can be accessed under “Event Calendar” in the Investors & Media section of the Company’s website.
- Simply Wall St.
Can Synlogic (NASDAQ:SYBX) Afford To Invest In Growth?
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
- Business Wire
Synlogic Provides Program and Business Update and Reports Third Quarter 2019 Financial Results
–SYNB1618 solid oral bridging study ongoing and SYNB1891 immuno-oncology study open –
- Insider Monkey
Synlogic, Inc. (SYBX) Is Burning These Hedge Funds
Before we spend days researching a stock idea we like to take a look at how hedge funds and billionaire investors recently traded that stock. Russell 2000 ETF (IWM) lagged the larger S&P 500 ETF (SPY) by more than 10 percentage points since the end of the third quarter of 2018. This means hedge funds […]
- Business Wire
Synlogic Announces Third Quarter 2019 Conference Call and Webcast
Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, announced today that the Company will release its third quarter 2019 financial results after the market closes on Tuesday, November 12, 2019. The press release will be followed by a conference call at 5:00 pm ET, which will be open to the public via telephone and webcast. During the conference call, the Company will review its financial results and provide a corporate update.
- Business Wire
Synlogic to Present at the Chardan 3rd Annual Genetic Medicines Conference
Synlogic, Inc. (SYBX) announced today that Aoife Brennan, M.B., B.Ch., Synlogic’s president and chief executive officer, will provide a corporate update at the Chardan 3rd Annual Genetic Medicines Conference on Monday, October 7 at 4:15 pm ET, in New York City. A live webcast of the presentation can be accessed under “Event Calendar” in the Investors & Media section of the Company’s website. Synlogic is pioneering the development of a novel class of living medicines, Synthetic Biotic medicines, based on its proprietary drug development platform.
- Thomson Reuters StreetEvents
Edited Transcript of SYBX earnings conference call or presentation 8-Aug-19 9:00pm GMT
Q2 2019 Synlogic Inc Earnings Call
- Simply Wall St.
Those Who Purchased Synlogic (NASDAQ:SYBX) Shares A Year Ago Have A 78% Loss To Show For It
The art and science of stock market investing requires a tolerance for losing money on some of the shares you buy. But...
- Benzinga
The Daily Biotech Pulse: Cheery Results For Sage's Depression Drug, UniQure Offering, Axsome Aces Study Of Headache Drug
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Sept. 4) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) Bioanalytical ...
- Benzinga
10 Biopharmaceutical Companies Trying To Cure Cancer
Cancer. Research shows nearly every sixth death in the world is due to the disease, making it the second leading cause of death behind cardiovascular diseases. The global pharmaceutical industry is estimated ...
- Zacks
Synlogic Discontinues Development of SYNB1020, Stock Down
Synlogic (SYBX) discontinues the development of its early-stage pipeline candidate, SYNB1020, for the treatment of hyperammonemia, following disappointing study results.
- Benzinga
The Daily Biotech Pulse: FDA Likes Nabriva's Antibiotic, Snubs Sarepta's DMD Drug; Moderna Gets Fast Track Designation For Zika Vaccine
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 19) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Avid ...
